Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1418731-10-8
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of tisotumab vedotin during breastfeeding. Because tisotumab is a large protein molecule with a molecular weight of about 153,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Vedotin (monomethyl auristatin E) is a small-molecule anticancer drug that might enter milk and be absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during enfortumab vedotin therapy and for 3 weeks after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]
- 2.
- Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
Substance Identification
Substance Name
Tisotumab Vedotin
CAS Registry Number
1418731-10-8
Drug Class
Breast Feeding
Lactation
Milk, Human
Antineoplastic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubMedLinks to PubMed
- Review Enfortumab Vedotin.[Drugs and Lactation Database (...]Review Enfortumab Vedotin.. Drugs and Lactation Database (LactMed®). 2006
- Review Polatuzumab Vedotin.[Drugs and Lactation Database (...]Review Polatuzumab Vedotin.. Drugs and Lactation Database (LactMed®). 2006
- Review Brentuximab Vedotin.[Drugs and Lactation Database (...]Review Brentuximab Vedotin.. Drugs and Lactation Database (LactMed®). 2006
- Review Inotuzumab Ozogamicin.[Drugs and Lactation Database (...]Review Inotuzumab Ozogamicin.. Drugs and Lactation Database (LactMed®). 2006
- Review Tisotumab vedotin for the treatment of cervical carcinoma.[Drugs Today (Barc). 2022]Review Tisotumab vedotin for the treatment of cervical carcinoma.Song X, Li R, Wang H, Song P, Guo W, Chen ZS. Drugs Today (Barc). 2022 May; 58(5):213-222.
- Tisotumab Vedotin - Drugs and Lactation Database (LactMed®)Tisotumab Vedotin - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...